Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Acquired by Gabelli Funds LLC

Gabelli Funds LLC raised its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 15.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,262,487 shares of the biopharmaceutical company’s stock after buying an additional 171,323 shares during the quarter. Gabelli Funds LLC owned about 1.21% of Revance Therapeutics worth $3,838,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of RVNC. Alliancebernstein L.P. raised its position in shares of Revance Therapeutics by 7.3% during the 4th quarter. Alliancebernstein L.P. now owns 3,497,112 shares of the biopharmaceutical company’s stock valued at $10,631,000 after acquiring an additional 236,641 shares in the last quarter. Magnetar Financial LLC raised its holdings in shares of Revance Therapeutics by 2.2% during the fourth quarter. Magnetar Financial LLC now owns 2,556,345 shares of the biopharmaceutical company’s stock worth $7,771,000 after purchasing an additional 56,174 shares during the period. State Street Corp raised its holdings in shares of Revance Therapeutics by 6.6% during the third quarter. State Street Corp now owns 2,433,963 shares of the biopharmaceutical company’s stock worth $12,632,000 after purchasing an additional 150,323 shares during the period. Geode Capital Management LLC lifted its position in shares of Revance Therapeutics by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 2,297,582 shares of the biopharmaceutical company’s stock worth $6,986,000 after buying an additional 7,928 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Revance Therapeutics by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 797,299 shares of the biopharmaceutical company’s stock valued at $2,424,000 after buying an additional 6,462 shares during the period. Institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Price Performance

Shares of Revance Therapeutics stock opened at $3.65 on Friday. Revance Therapeutics, Inc. has a 1-year low of $2.30 and a 1-year high of $6.65. The business’s fifty day moving average price is $3.65 and its two-hundred day moving average price is $3.93. The company has a market capitalization of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on RVNC shares. StockNews.com began coverage on shares of Revance Therapeutics in a research note on Friday, April 11th. They set a “hold” rating on the stock. Barclays dropped their price target on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Monday, December 23rd. Finally, Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Nine analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $8.39.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.